Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Alteration of gene expression is fundamental to many diseases. A better understanding of how epigenetic proteins affect diseases provides a starting point for therapy development and the discovery of new drug. We hope that this area of rersearch will ultimately provide leads to finding new treatments for dementia.

Q: What is the link between genes, chemistry and new drugs?

PB: Chemistry sits between a gene and a drug, and what sits in there as well is the field I work in which is epigenetics. Genes control our body but every cell in the body has the same genes and we have very different cells: red blood cells, neurones, bone cells. Those genes are exquisitely controlled by a system called epigenetics. Drug discovery sits between the genes and the medicine and tries to manipulate those genes to actually treat a disease. In epigenetics, which is a new area I work in, we try to link up with drug discovery and use drugs to control genes to treat disease.

Q: How do you go about finding new drugs?

PB: It is a complicated process, of course. We have to first identify a target, which is a protein or something in a cell that we think is doing the wrong thing, and we want to identify that which is the most challenging part. From there we try to develop a way of testing something against that protein or that target and we also try to find new molecules that will interfere with that, hopefully in a positive way, to have a therapeutic effect.

Q: What drug targets has your work focused on?

PB: We are currently working on epigenetic targets. We think that epigenetics are key to controlling how genes are expressed. We try to find molecules that will affect epigenetic proteins, to try and affect those genes as drugs.

Q: What are the most important lines of research that have emerged in this field over the past 5 to 10 years?

PB: The whole field of epigenetics drug discovery is fairly new, it's only been in the past 5-10 years that people have actually looked at it. The concept that drugs can work by turning genes on and off is a new idea. We are seeing effects initially in cancer but we hope to see epigenetic drug discovery be used in many other areas. The concept that epigenetics applies to many different diseases is a pretty new idea.

Q: Why is your line of research important, why should we fund it?

PB: What we will be doing now is looking at treatments for dementia. Dementia is a horrible disease that affects almost 1 in 10 people in the UK over the age of 65; Alzheimer's disease is the most common form of dementia. As people live longer, they don't die as frequently from heart disease or cancer, the number of people getting dementia is increasing dramatically; that is horrible for them, for their families and also for all of us as tax payers who have to pay the NHS to take care of these people. Although that may sound very negative, there is a lot of research going on in dementia and we would like to help in that process to find drugs for dementia. Due to our existing interest in epigenetics, we want to find new drugs that utilise epigenetic pathways and modulate those genes that we think will be useful in dementia.

Q: How does your research fit into translational medicine within the department?

PB: In the Nuffield Department of Medicine we span a whole range of research, from a very early understanding of biology and how cells and biological systems work, all the way to testing things in a clinical trial to see if they are actually useful as drugs. Medicinal chemistry sits in the middle of that. We don't really do the basic science, we take the basic science and understanding of how disease and biology work, pick out those key targets that we think are useful to interfere with, and try to develop treatments for them. If we find something useful then eventually that will be tested at the far end of the transitional pipeline in the clinic.

Paul Brennan

Medicinal Chemistry

Professor Paul Brennan research focusses on epigenetics: the mechanisms that control gene expression. He studies how chemical probes interfere with epigenetic enyzmes that can be targeted to treat various diseases. Epigenetics combined with disease biology will ultimately accelerate drug discovery.

More podcasts related to Translational & Clinical

Anna Gloyn: Genetics and Diabetes

Predictions suggest that by 2030, 366 million people worldwide will be affected by diabetes, a disease which already uses 10% of the NHS budget. Continued breakthroughs in the area of genetics related to different types of diabetes enable better diagnosis and treatment for patients and identify novel pathways that can be targeted for therapeutic interventions.

Erika Mancini: Chromatin Remodelling

Chromatin plays an important role in the regulation of gene expression. The movement of nucleosomes, packing and unpacking DNA, is governed by chromatin remodelling ATPases. Malfunctions in the regulation of chromatin structure often leads to complex multi-system diseases and cancer, notably leukemia.

Diabetes and Genomics by Mark McCarthy

Diabetes and obesity are both major challenges for global healthcare, with the social, health and economic costs over the next fifty years being in the ‘trillions’ of dollars. Genetics is one of the more important tools for developing a systematic understanding of the disease and how best to treat it in different patients.

Silvia Paracchini: Dyslexia and Genetics

Dyslexia is an impairment in learning to read that affects up to 10% of children; it can have profound effects on an individual life. Dyslexia has an important genetic component; candidate genes control important stages during foetal brain development. Understanding the biology of dyslexia could help us design more effective diagnostic criteria and treatment plans.

Claire Palles: Gastrointestinal cancers

The gastrointestinal track is responsible for more cancers than any other system. A condition called Barrett's oesophagus, characterised by a change in the cells lining the oesophagus, can lead to oesophageal adenocarcinoma. Only few people with Barrett's oesophagus will go on to develop cancer, and genome sequencing studies aim to identify genetic risk factors and therefore better target high-risk patients.

Antonio Velayos-Baeza: Rare neurological disorders

ChAc is a rare progressive neurological disorder caused by mutations in a very complex gene. A better understanding of the biology underlying this disease helps develop better diagnostic tools, and opens up the possibility of discovering targets for possible future treatments.

Zamin Iqbal: Computation and genetics

Resistance to drugs in bacteria can be aquired by swapping genes between individual bacteria. Computer programs developed by Dr Iqbal enable doctors to predict which antibiotics will be met with drug resistance, enabling the selection of the right drug. His work also enables the tracking of an infection from patient to patient, as well as the tracking of the spread of an infection within a hospital.

Gerton Lunter: The evolution of the genome

Computational and stastistical methods help us understand evolution as well as genetic disease. Looking at our genomes opens up clinical possibilities, for example in cancer, allowing more genes to be looked at - more quickly and more cheaply, wich can impact prognosis and treatment selection.

Catherine Green: DNA replication and Cancer

The process of DNA replication is complex, and mistakes can lead to genome instability. Surveillance systems are not always successful which results in mutations that have the potential to inactivate genes or change their activity. This can lead to cancer, and many chemotherapeutic drugs are designed to disrupt DNA replication. A better understanding of these mechanisms can help us develop new drugs with reduced side effects.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.